FDA Approves Topical PDE4-Inhibitor Roflumilast for Psoriasis
The US Food and Drug Administration (FDA) has approved roflumilast 0.3% cream for the topical treatment of plaque psoriasis, "including ...
The US Food and Drug Administration (FDA) has approved roflumilast 0.3% cream for the topical treatment of plaque psoriasis, "including ...
© 2022 Pharma News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy.
© 2022 Pharma News Hubb All rights reserved.